Chervonskiĭ A V, Suslov A P, Shitin A G, Abronina I F, Brondz B D
Biull Eksp Biol Med. 1986 Jul;102(7):56-8.
F1(MSU X WAG) rats were immunized with anti B6 BALB/c specific suppressor T cells (SSTC), purified by absorption/elution technique, with the following fusion of splenocytes to NS-I myeloma cell line. Hybrids were screened for their ability to affect SSTC, cytotoxic T lymphocytes (CTL) and producers of macrophage migration inhibition factor (MIF-producers) all triggered by in vivo priming with allogeneic cells. Two hybridoma cell lines--C1 and C4 inactivated SSTC by approximately 50%, leaving CTL and MIF-producers intact. C4 were also active in vivo, if injected as ascitic fluid from nu/nu mice, though to a lesser extent than in vitro.
将经吸收/洗脱技术纯化的抗B6 BALB/c特异性抑制性T细胞（SSTC）免疫F1（MSU×WAG）大鼠，随后将脾细胞与NS-1骨髓瘤细胞系进行如下融合。筛选杂交瘤细胞，观察其对由同种异体细胞体内致敏引发的SSTC、细胞毒性T淋巴细胞（CTL）以及巨噬细胞移动抑制因子产生细胞（MIF产生细胞）的影响能力。两个杂交瘤细胞系——C1和C4使SSTC失活约50%，而CTL和MIF产生细胞保持完整。若将C4作为裸鼠腹水中的细胞进行注射，其在体内也具有活性，尽管活性程度低于体外。
